Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- Conditions
- Invasive Breast CarcinomaPrognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Procedure: LumpectomyProcedure: MastectomyRadiation: Radiation Therapy
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 2175
- Registration Number
- NCT04266249
- Locations
- 🇺🇸
Mercy Cancer Center-West Lakes, Clive, Iowa, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
🇺🇸Ann M Wierman MD LTD, Las Vegas, Nevada, United States
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 15
- Registration Number
- NCT04253561
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain
🇪🇸Hospital Universitario del Vall d' Hebron, Barcelona, Spain
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Conditions
- Advanced HER2+Breast Cancer
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04208178
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of California LA, Los Angeles, California, United States
🇪🇸Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1560
- Registration Number
- NCT04193059
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Conditions
- Metastatic Breast CancerBreast CancerAdvanced Breast CancerEndometrial Cancer
- Interventions
- Drug: Aromatase Inhibitor (AI)
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT04188548
- Locations
- 🇺🇸
Winship Cancer Center Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Conditions
- Breast CancerNeoadjuvant Chemotherapy
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT04172259
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2907
- Registration Number
- NCT04158258
- Locations
- 🇧🇷
Instituto Brasileiro De Controle Do Câncer - IBCC, São Paulo, Brazil
🇦🇷Sanatorio de la Mujer, Rosario, Argentina
🇧🇷Hospital Jardim Amália, Volta Redonda, Rio De Janeiro, Brazil
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
- Conditions
- HER2-positive Early Breast Cancer
- Interventions
- Procedure: SurgeryRadiation: Post-Operative Radiotherapy
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT04024462
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 46
- Registration Number
- NCT03988036
- Locations
- 🇩🇪
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie, Georgsmarienhütte, Lower Saxony, Germany
🇩🇪Mammazentrum Hamburg, Hamburg, Germany
🇩🇪Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Bavaria, Germany
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Conditions
- Early-stage Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.